Peptidomimetics Development Platform
Peptidomimetics refers to compounds that have a secondary structure compared with natural peptides and retain other similar structural characteristics of natural peptides. Our company's peptidomimetics development platform has rich experience in cooperation with the global pharmaceutical industry, and we employ world-class scientists to build platforms and develop innovative technologies for peptidomimetics development services, which have the ability to speed up your rare disease research process.
Overview of Peptidomimetics
Peptides are widely used in the treatment of diseases, but natural endogenous peptides have many limitations of their own, such as sensitivity to proteases and insufficient membrane permeability. Peptidomimetics can be prepared through the medicinal chemistry approach and biophysical approach, by appropriately modifying the functional properties of the initial peptide. This breaks through the limitations of the initial peptide and achieves higher bioavailability and oral bioavailability, while reducing side effects and protease degradation.
Classification of Peptidomimetics
Historically, peptidomimetics are usually divided into three classes: type I mimetics (structural mimetics), type II mimetics (functional mimetics), and type III mimetics (functional-structural mimetics). Recently, a new classification has been proposed, which is specifically divided into:
Class A mimetics
Class A mimetics only introduce a limited number of modified amino acids based on the parent peptide to achieve the purpose of stabilizing biological activity.
Class B mimetics
Class B mimetics are constructed by introducing non-naturally amino acids, small molecule building blocks and/or major backbone alterations.
Class C mimetics
Class C mimetics are highly modified, completely replacing the peptide backbone, and have an obvious small molecule structure.
Class D mimetics
Class D mimetics are the least similar to the parent peptide. The generation methods of this molecule include: affinity optimization of class C molecules, compound library screening or in silico screening.
As a CRO with multi-platform capabilities, our company has been committed to the research of rare diseases and can provide you with comprehensive peptidomimetics development services and preclinical research services, including PK studies and safety evaluation.
- Peptidomimetic Library Screening
We have established a rich peptidomimetic library that can meet the needs of screening various structures, including thousands of α-helix and β-turn mimetic selects.
- Target-based Peptidomimetic Development
The target-based peptidomimetic development services that we can provide include but are not limited to:
- Signaling Molecule Target-based Peptidomimetic
- Nucleic Acid Target-based Peptidomimetic
- Transcription Factor Target-based Peptidomimetic
- Enzyme Target-based Peptidomimetic
- Receptor Target-based Peptidomimetic
- Function-based Peptidomimetic Development
The function-based peptidomimetic development services that we can provide include but are not limited to:
- Anti-Oxidant Peptidomimetic
- Anti-Glycation Peptidomimetic
- Anti-Viral Peptidomimetic
- Anti-Cancer Peptidomimetic
- Anti-Malarial Peptidomimetic
- Analgesic Peptidomimetic
- Anti-Microbial Peptidomimetic
- Immunosuppressive Peptidomimetic
In addition to the above services, we provide a variety of peptidomimetics for you to choose from, include but are not limited to:
|Peptide bond isosters
|β / γ -amino acids
Why Choose Us?
- One-stop platform with an experienced technical team
- Careful design and transparent operation process
- High data quality and reliable analysis
- Stringent quality control and testing
- Ability to customize products and services
- Global reach and distribution network
With a research team with extensive expertise in rare disease therapy research and development, our company is confident in providing customers with peptidomimetics development. We can quickly respond to the changing needs of your rare disease research projects. If you are interested in our services, please feel free to contact us for more details and quotation information of related services.
- Trabocchi, Andrea. "Principles and applications of small molecule peptidomimetics." Small molecule drug discovery. Elsevier, 2020. 163-195.
- Pelay‐Gimeno, Marta, et al. "Structure‐based design of inhibitors of protein–protein interactions: mimicking peptide binding epitopes." Angewandte Chemie International Edition 54.31 (2015): 8896-8927.
All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.